Notoginsenoside R1 for Organs Ischemia/Reperfusion Injury: A Preclinical Systematic Review

Notoginsenoside R1 (NGR1) exerts pharmacological actions for a variety of diseases such as myocardial infarction, ischemic stroke, acute renal injury, and intestinal injury. Here, we conducted a preclinical systematic review of NGR1 for ischemia reperfusion (I/R) injury. Eight databases were searched from their inception to February 23rd, 2019; Review Manager 5.3 was applied for data analysis. CAMARADES 10-item checklist and cell 10-item checklist were used to evaluate the methodological quality. Twenty-five studies with 304 animals and 124 cells were selected. Scores of the risk of bias in animal studies ranged from 3 to 8, and the cell studies ranged from 3 to 5. NGR1 had significant effects on decreasing myocardial infarct size in myocardial I/R injury, decreasing cerebral infarction volume and neurologic deficit score in cerebral I/R injury, decreasing serum creatinine in renal I/R injury, and decreasing Park/Chiu score in intestinal I/R injury compared with controls (all P
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research

Related Links:

AbstractA genome-wide association study (GWAS) reported that the single nucleotide polymorphism (SNP) rs4618210 in thePLCL2 gene is related to myocardial infarction (MI) in the Japanese population, but no study has examined the correlation ofPLCL2 with ischemic stroke (IS). The present study was designed to investigate whether the genetic variation inPLCL2 is associated with large artery atherosclerotic (LAA) stroke in a Han Chinese population. Tagging SNPs (tSNPs) of thePLCL2 gene were determined by a fine-mapping strategy and were genotyped by improved multiplex ligation detection reaction (iMLDR) technology in 669 LAA s...
Source: Journal of Molecular Neuroscience - Category: Neuroscience Source Type: research
AbstractThere are few reports investigating the relationship between bronchial asthma (BA) and heart failure (HF). We hypothesized BA may have impact on prognosis in patients with HF. Among 323 consecutive outpatients with HF, 191 patients without chronic obstructive pulmonary disease were analyzed. Twenty patients had BA, most of whom (80.0%) had preserved left ventricular ejection fraction (LVEF  ≥ 50%). The use of β-blockers was less frequent (55.0% vs 83.0%.p = 0.01), systolic blood pressure (133 ± 22 vs 120 ± 17 mmHg,p = 0...
Source: Heart and Vessels - Category: Cardiology Source Type: research
AbstractPurpose of the ReviewThis review highlights selected cardiovascular disease (CVD) prevention studies presented at the 2019 American Heart Association (AHA) Scientific Sessions.Recent FindingsSeveral important cardiovascular prevention studies were presented at the 2019 AHA Scientific Sessions. Results from the Colchicine Cardiovascular Outcomes Trial (COLCOT) showed that low-dose colchicine reduces the risk of recurrent CVD events among patients with recent myocardial infarction. A prospective analysis from the UK Biobank cohort demonstrated that the increased CVD risk associated with clonal hematopoiesis of indete...
Source: Current Atherosclerosis Reports - Category: Cardiology Source Type: research
AbstractBackgroundImpaired renal function (IRF) is associated with increased risks of both ischemic and bleeding events. Ticagrelor has been shown to provide greater absolute reduction in ischemic risk following acute coronary syndrome (ACS) in those with versus without IRF.MethodsA pre-specified sub-analysis of the randomized GLOBAL LEADERS trial (n = 15,991) comparing the experimental strategy of 23-month ticagrelor monotherapy (after 1-month ticagrelor and aspirin dual anti-platelet therapy [DAPT]) with 12-month DAPT followed by 12-month aspirin after percutaneous coronary intervention (PCI) in ACS and sta...
Source: Clinical Research in Cardiology - Category: Cardiology Source Type: research
Publication date: Available online 7 January 2020Source: The Lancet Diabetes &EndocrinologyAuthor(s): Hertzel C Gerstein, Robert Hart, Helen M Colhoun, Rafael Diaz, Mark Lakshmanan, Fady T Botros, Jeffrey Probstfield, Matthew C Riddle, Lars Rydén, Charles Messan Atisso, Leanne Dyal, Stephanie Hall, Alvaro Avezum, Jan Basile, Ignacio Conget, William C Cushman, Nicolae Hancu, Markolf Hanefeld, Petr Jansky, Matyas KeltaiSummaryBackgroundCardiovascular outcome trials have suggested that glucagon-like peptide 1 (GLP-1) receptor agonists might reduce strokes. We analysed the effect of dulaglutide on stroke within the ...
Source: The Lancet Diabetes and Endocrinology - Category: Endocrinology Source Type: research
Publication date: January 2020Source: Archives of Cardiovascular Diseases Supplements, Volume 12, Issue 1Author(s): C. Bernard, M.C. Morgant, A. Jazayeri, A. Bernard, O. BouchotDuring acute phase of myocardial infarction (MI), the culprite artery must be revascularized quickly with angioplasty. Then, surgery complete the procedure in a second time. If surgery is emergent, resulting death rate is really high; 15 to 20% of patients operated on within the first 48 hours and 4 to 5% for patients operated on after. Various factors influence mortality rate; timing of surgical revascularization and patient's preoperative sta...
Source: Archives of Cardiovascular Diseases Supplements - Category: Cardiology Source Type: research
ConclusionAmong patients with AF, OSA is an independent risk factor for MACNE and, more specifically, stroke/SE.Graphical Abstract
Source: American Heart Journal - Category: Cardiology Source Type: research
Low-dose aspirin reduces the frequency of adverse vascular events in those at increased risk of occlusive cardiovascular disease (CVD). People who benefit include those: with a history of myocardial infarction, ischaemic stroke, unstable or stable angina, peripheral arterial disease, or atrial fibrillation (1). The pathophysiology of CVD risk contributes to cognitive decline through multiple pathways that include cerebral hypo-perfusion, hypoxia, hippocampal atrophy, emboli, or infarcts (2,3). However, the value of aspirin use in prevention of cognitive impairment remains uncertain since results relating to the influence o...
Source: Maturitas - Category: Primary Care Authors: Source Type: research
AbstractBackgroundData about the clinical outcomes of ACS patients with advanced renal dysfunction (estimated glomerular filtration rate  
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
CONCLUSIONS: In patients with appropriate indications according to Chinese AUC, coronary revascularization was associated with significantly lower risk of MACCEs at 1 year. No benefit was found in coronary revascularization in patients with inappropriate indications. Our findings provide evidence for using Chinese AUC to guide clinical decision-making. CLINICAL TRIAL REGISTRATION: NCT02880605. https://www.clinicaltrials.gov. PMID: 31923098 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
More News: Antidoxidants | Brain | Databases & Libraries | Drugs & Pharmacology | Heart Attack | Ischemic Stroke | Neurology | Stroke | Study